The Approval Process in Action

Source: The Life Sciences Report and Visual Capitalist (5/1/13)

What catalysts in the drug development process move biotech company stocks? The savvy investor must know what steps in the U.S. Food and Drug Administration's approval process can propel a stock up or down. From drug discovery to the much-anticipated PDUFA date, The Life Sciences Report and the Visual Capitalist have collaborated on an infographic that describes both the process and related catalysts.

Analyst: 'New CEO, Larger Sales Team and Greater SUI Focus Should Help Medical Device Growth'
Source: Streetwise Reports (05/23/2018)

Cowen analyst Dr. Joshua Jennings highlighted this medical device firm’s Q1/18 developments and financial results.

Biotech Announces Encouraging HIV Vaccine Results
Source: Streetwise Reports (05/23/2018)

Ram Selvaraju, an analyst with H.C. Wainwright & Co., explained the recently released data from a study of one of this immunotherapy firm's therapeutics.

Shovelnose Delivers Gold to Westhaven
Source: Bob Moriarty for Streetwise Reports (05/17/2018)

Bob Moriarty of 321 Gold profiles a company that holds a large land position in the "most unexplored gold belt in British Columbia."

Cancer in the Crosshairs: IMV Looks to Deliver Immunotherapy a New Way
Source: Streetwise Reports (05/16/2018)

In this interview with The Life Sciences Report, IMV Inc.'s CEO Fred Ors and Pierre Labbè, chief financial officer, describe the innovative immunotherapy platform technology that has attracted partnerships with big pharma, prompted reorganization of the company, and holds long-term promise for cancer patients.

Biotech's Launch of Pain Product Shows Encouraging Early Metrics
Source: Streetwise Reports (05/12/2018)

Francois Brisebois, an analyst with Laidlaw & Co., reviewed this firm's progress since commercially debuting its primary asset.

Cell Therapy Firm Finalizing $5.1M Strategic Investment and Partnership with Chinese Company
Source: Streetwise Reports (05/09/2018)

The terms of a proposed agreement between this cell therapy company and YOFOTO, a Chinese health and consumer products company, have been revised and will result in a $5.1 million investment.

Concurrent Milestones for Biotech Set to Occur 'on the Horizon'
Source: Streetwise Reports (05/09/2018)

Analyst Douglas Loe with Echelon Wealth Partners discussed this immunotherapy developer's recent and upcoming news.

In the second of a two-part series exploring the disruptive cell therapy space, Maxim Group analyst Jason McCarthy takes a look at small-cap companies targeting big-ticket indications and their potential to drive blockbuster value for both patients and investors.

Risk Versus Reward: The Value of Cell Therapy for Patients and Investors
Source: Streetwise Reports (04/25/2018)

The cell therapy space, encompassing disruptive new treatment including stem cell therapy, immunotherapy and gene editing, has begun to mature, with a handful of product approvals and others in late-stage development. In the first of a two-part series examining the disruptive technology, Maxim Group analyst Jason McCarthy exposes the upsides and downsides of the space, and the companies at its forefront.

Analyst Sees Tenbagger in Biotech Firm with 'Favorable Updates'
Source: Streetwise Reports (04/24/2018)

Ram Selvaraju, an analyst with H.C. Wainwright & Co., relayed the most recent news concerning this firm's drug candidate.